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clinical outcomes and management strategy of patients with SMI presenting 
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Methods: All AMI hospitalizations from the National Inpatient Sample were 
included, stratified by mental health status in to 5 groups: no-SMI, 
Schizophrenia, 'Other non-organic psychoses' (ONOP), Bipolar Disorder and 
Major Depression. Regression analyses were performed to assess the 
association (adjusted odds ratios, p≤0.001 for all outcomes) between SMI 
subtypes and clinical outcomes. 
Results: Out of 6,968,777 AMI hospitalizations between 2004 and 2014, 
439,544 (6.5%) had an SMI diagnosis. Although patients with Schizophrenia 
and ONOP experienced higher crude rates of in-hospital mortality and 
stroke compared to those without SMI, only Schizophrenia patients were at 
increased odds of mortality (1.10[1.04,1.16]), while ONOP were the only 
group at increased odds of stroke (1.53[1.42,1.65]) following 
multivariate adjustment. Patients with ONOP were the only group 
associated with increased odds of in-hospital bleeding compared to those 
without SMI (1.11[1.04,1.17]). All SMI subtypes were less likely to 
receive coronary angiography and PCI, with the Schizophrenia group being 
at least odds of either procedure (0.46[0.45,0.48] and 0.57[0.55,0.59], 
respectively). 
Conclusion: Schizophrenia and 'other non-organic psychoses' are the only 
SMI subtypes associated with adverse clinical outcomes after AMI. 
However, all patients with SMI were less likely to receive invasive 
management for AMI, with women and schizophrenia diagnosis being the 
strongest predictors of conservative management. A multidisciplinary 
approach between psychiatrists and cardiologists could improve outcomes 
of this high-risk population. 
 
 
 
 
  
 
 
Dear Professor Stanley Nattel, MD, Editor in Chief, 
 
 We thank the Editorial Committee and the Reviewers for their valuable comments on 
the manuscript entitled ‘Acute Myocardial Infarction in Severe Mental Health Illness: 
prevalence, clinical outcomes and process of care in United States hospitalizations.’ and feel 
that these recommendations have improved the quality of our manuscript. We have attempted 
to answer all the comments fully as outlined in the rebuttal and tracked all new changes in the 
manuscript. Furthermore, we acknowledge all the recommendations by the Editor-in-Chief 
and Editorial manager and can confirm that all the requested changes have been made 
including reducing the word count to 5600 words.  
 We hope that we have addressed all reviewers’ and editorial manager’s comments 
sufficiently and hope that these changes will enable publication of our paper in the Canadian 
Journal of Cardiology. 
 As per your request we can confirm the following:  
1. No portion of the text has been copied from other material in the literature (unless in 
quotation marks, with citation). 
 
2. We are aware that it is the author's responsibility to obtain permission for any figures or 
tables reproduced from any prior publications, and to cover fully any costs involved. Such 
permission must be obtained prior to final acceptance. However, we have not reproduced any 
figures or tables from prior publications. 
 
We list our reply to the reviewer’s comments in the file entitled ‘Response to 
Reviewers’ as per journal instructions. 
 
Yours sincerely 
 
Mohamed Mohamed and Mamas Mamas 
On behalf of submitting authors 
*Cover Letter
Responses to Reviewers 
 
Reviewer #1:  
 
Comment 1. It would be very interesting and important for the readers of CJC to see an 
analysis looking at temporal trends of outcomes from 2004 to 2014. 
 
Response: We thank the reviewer for kindly highlighting this important aspect of the analysis. 
We have performed a temporal analysis of clinical outcomes and receipt of invasive 
management and have provided the data in Table S5 (clinical outcomes) and Figure S2 
(growth of coronary angiography and PCI). Furthermore, we have updated the ‘Results’ 
sections with the respective findings (quoted below).  
 
Under ‘Utilization of invasive management’ subheading:  
 “There was a notable increase in the rates of both coronary angiography and PCI in 
all the groups over the study period (Figure S2).” 
 
Under ‘In-hospital MACCE, Mortality and Stroke’ subheading: 
“A temporal analysis of outcomes demonstrates an overall decline in the rates of 
MACCE, mortality and acute stroke/TIA in all the study groups except the ONOP and 
Bipolar disorder groups whose rates of MACCE and acute stroke/TIA have either increased 
or remained the same (Table S5). However, the pattern of differences in rates of MACCE, 
morality and stroke between groups remained the same throughout the study period.” 
 
Under ‘In-hospital Bleeding’ subheading: 
“The rate of all-cause bleeding increased in all groups over the study period but 
remained higher in SMI groups compared to patients without SMI, with the exception of 
ONOP group whose rates of bleeding were higher than patients without SMI. (Table S5)” 
 
 
Comment 2. In addition, please provide an analysis looking at the differences in outcomes 
between NSTE-ACS and STEMI. 
 
Response: We have performed an analysis of outcomes according to the type of MI (STEMI 
vs. NSTEMI) and presented the findings in Table S6. Furthermore, we have created a 
dedicated subheading in the ‘Results’ section to report our findings (quoted below).  
 
“Sensitivity Analysis 
 A sensitivity analysis according to AMI type (STEMI vs. NSTEMI) was performed to exclude 
examine differences in outcomes between both AMI presentations. Overall, the findings in the 
STEMI and NSTEMI groups were generally similar to those found in the total cohort. (Table 
S6) However, certain differences were observed within AMI subgroups. In the NSTEMI 
subgroup, patients with Bipolar Disorder were associated with reduced odds of MACCE 
compared to those without SMI while there was no difference in MACCE and all-cause 
bleeding between patients without SMI and those with ONOP. In the STEMI subgroup, there 
was no difference in mortality and all-cause bleeding between patients with Bipolar Disorder 
group and those without SMI as was the case in all-cause bleeding between patients with 
Major Depression and those without SMI.” 
 
*Detailed Response to Reviewers
Comment 3. It would be worth to run a multivariable analysis according to gender rather than 
just presenting crude rates.  
 
Response: We thank the reviewer for this suggestion. We have conducted a multivariable 
analysis according to gender with male gender being the reference group. The findings are 
summarized in Table S7 and the ‘Results section’ has been updated accordingly (quoted 
below).  
 
Under ‘Utilization of invasive management’ subheading:  
“The rates of coronary angiography and PCI were also lower amongst women across 
all study groups, including patients without an SMI diagnosis (Figure 3), a finding that 
persisted in multivariate analysis (Table S7). However, the odds of receipt of coronary 
angiography between genders were not significant in the Schizophrenia and Major 
Depression groups. “ 
 
Under ‘In-hospital MACCE, Mortality and Stroke’ subheading: 
“In multivariable analysis, the odds of MACCE were increased in women without 
SMI and those with Bipolar Disorder and Major Depression, primarily driven by increased 
odds of acute stroke in these groups. (Table S7) In contrast to the other groups, women with 
ONOP were associated with reduced odds of MACCE and stroke compared to men (Table 
S7). Furthermore, women without SMI and those with ONOP and Major Depression were at 
reduced odds of mortality compared to men, while there was no difference in mortality 
between genders in the Schizophrenia and Bipolar Disorder groups.” 
 
Under ‘In-hospital Bleeding’ subheading: 
“A multivariate analysis according to gender revealed increased odds of bleeding in 
women without SMI as well as those with Schizophrenia and Major depression 
(Supplementary Material - Table S7). In contrast, no difference in bleeding was found 
between genders in patients with ONOP and women with Bipolar disorder were at reduced 
odds of bleeding.” 
 
Furthermore, we have updated the relevant section in the ‘Discussion’ section, which now 
reads as follows: 
 
“We found women in all study group to be associated with lower or insignificant odds 
of mortality compared to men, but also at increased odds of acute stoke/TIA, except in those 
with ONOP where the was no difference between genders. Women with Schizophrenia were 
also associated with the highest odds of bleeding complications compared to men. However, 
women of all subgroups were much less likely to undergo invasive management compared to 
men, especially women with Bipolar Disorder who were 15% and 34% less likely to receive 
coronary angiography and PCI, respectively.” 
 
Comment 4. I liked your figures in Forest plots, so, could you illustrate the aOR of PCI and 
coronary angiography as well? 
 
Response: We are grateful for the reviewers’ kind remarks. Figure 6 now includes forest plots 
of aOR for receipt of coronary angiography and PCI. The figure is also attached below:  
 
*Reference group is No-SMI; § non-significant (p≥0.05); † p<0.001; CI: confidence interval; 
ONOP: Other non-organic psychoses; SMI: Severe mental illness 
 
 
 
Comment 5. Please maintain consistency in US or UK spelling. I noticed that the tables are 
spelt in British English and the manuscript is in American English with random words e.g. 
‘centre’ and ‘analysed’ in British English. 
 
Response: We thank the reviewer for highlighting this issue. This issue has now been rectified 
and all the text has been modified to US English spelling.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Reviewer #2:  
 
 
Comment 1. The second and third sentences of the Results section of the Abstract sound 
partly contradictory and need to be read more than once to be understood: "Patients with 
Schizophrenia and ONOP experienced higher crude rates of in-hospital mortality and stroke 
compared to those without SMI. However, only Schizophrenia was associated with increased 
odds of mortality (aOR: 1.10[1.04,1.16]) and only ONOP were associated with increased 
odds of stroke (aOR: 1.53[1.42,1.65])." Consider rewriting this to make it clearer. 
 
Response: We thank the reviewer for highlighting the lack of clarity of the aforementioned 
statement and we can confirm that this has now been changed to further clarify its intended 
meaning. The new statement reads as follows (also highlighted in the manuscript):  
 
“Although patients with Schizophrenia and ONOP experienced higher crude rates of in-
hospital mortality and stroke compared to those without SMI, only Schizophrenia patients 
were at increased odds of mortality (1.10[1.04,1.16]), while ONOP were the only group at 
increased odds of stroke (1.53[1.42,1.65]) following multivariate adjustment.” 
 
 
Comment 2. Consider briefly speculating in the Discussion on why the proportion of MI 
patients with major depression has increased so dramatically over the study period. Has 
major depression become more common on the population at risk for MI? Is major 
depression being coded more often, with less real change in prevalence? 
 
Response: Thank you for highlighting this important point that is lacking in the discussion. 
There is data from several nationwide studies to suggest that the prevalence of both major 
depression and bipolar disorder has increased in the background population (references 
below). Nevertheless, we agree with the reviewer that the increase in prevalence may be due 
to major depression being coded more frequently. We have added a paragraph to the 
discussion to emphasize both possibilities to readers. The paragraph reads as follows:  
“The present study is the first to examine the prevalence of SMI in the AMI 
population and shows a rise in the prevalence of SMI over an eleven-year horizon, primarily 
due increasing rates of Major Depression and Bipolar disorder diagnoses. Although these 
findings are in keeping with previous reports of trends in the general population, it is 
possible that that these diagnoses have been coded more frequently in later years due to 
physicians’ awareness of their implications in the context of AMI hospitalizations” 
 
References:  
 Sara GE, Malhi GS. Trends in diagnosis of bipolar disorder: Have the boundaries 
changed? Aust. N. Z. J. Psychiatry. 2015;49:1021-1028. 
 Weinberger AH, Gbedemah M, Martinez AM, Nash D, Galea S, Goodwin RD. 
Trends in depression prevalence in the USA from 2005 to 2015: widening disparities 
in vulnerable groups. Psychol. Med. 2018;48:1308-1315. 
 Jeuring HW, Comijs HC, Deeg DJH, Stek ML, Huisman M, Beekman ATF. Secular 
trends in the prevalence of major and subthreshold depression among 55–64-year olds 
over 20 years. Psychol. Med. 2018;48:1824-1834. 
 
 
 
Comment 3. How accurate are co-morbidities coded, specifically ones such as dyslipidemia 
and family history of coronary disease? 
 
 
Response: As with most administrative datasets, an inherent limitation is the possible coding 
inaccuracy and the reliance on data that has been collected in retrospect. However, we have 
stated this as our first limitation in the manuscript’s ‘limitations’ section, ‘‘The are several 
limitations to the present study. First, the NIS is an administrative dataset that is susceptible 
to coding. Although the identification of ACS and SMI diagnoses as well as other 
comorbidities was based on the use of administrative codes, ICD-9 codes have been 
previously validated for the purposes of cardiovascular research.’’  
References:  
 Birman-Deych E et al. Accuracy of ICD-9-CM codes for identifying cardiovascular 
and stroke risk factors. Med Care. 2005. May;43(5):480-5.  
 DeShazo et al.  A comparison of a multistate inpatient EHR database to the HCUP 
Nationwide Inpatient Sample; BMC Health Services Research (2015) 15:384 DOI 
10.1186/s12913-015-1025-7) 
 
More specifically, the NIS has been previously validated for the purpose of cardiovascular 
research in regard to its demographic capture. We have clarified this in our ‘Methods’ section 
under the ‘Data source’ subheading (now in Supplementary Material - Appendix B to reduce 
the word count based on the Editorial Office’s request):  
 
‘The estimates of hospital characteristics, numbers of discharges, length of stay, and in-
hospital mortality from the HCUP Nationwide Inpatient Sample (NIS) for 2007 were highly 
comparable to three related data sources: the American Hospital Association (AHA) Annual 
Survey Database, the National Hospital Discharge Survey (NHDS) from the National Center 
for Health Statistics, and the MedPAR inpatient data from the Centers for Medicare and 
Medicaid Services (CMS). Furthermore, NIS was found to have a more comprehensive 
demographic capture when compared to a large multistate EHR dataset in more than 25 
diagnosis groups, including cardiovascular disorders’ 
 
References:  
 Barrett M WE, Whalen D. HCUP Nationwide Inpatient Sample (NIS) Comparison 
Report. HCUP Methods Series Report. 2007.  
 DeShazo JP, Hoffman MA. A comparison of a multistate inpatient EHR database to 
the HCUP Nationwide Inpatient Sample. BMC health services research. 2015;15:384. 
 
 
Comment 4. The authors state (page 4) that SMI patients are under-represented in clinical 
trials. It might be more accurate and comprehensive to state that SMI is usually an exclusion 
factor in cardiovascular trials, or SMI patients are excluded because they are unable to 
reliably complete follow-up and comply with treatment. 
 
Response: We thank the reviewer for their suggestion and completely agree with that a 
rephrase of the statement to elaborate why SMI patients are under-represented in clinical 
trials would be more insightful. The aforementioned sentence has now been changed to the 
following:  
“Acute myocardial infarction (AMI) is the commonest manifestation of CVD but there is 
limited literature on the prevalence, treatment strategies and clinical outcomes of patients 
with SMI who are often excluded from clinical trials due to concerns about their adherence 
to cardiovascular medications and follow-up.” 
 
 
Comment 5. The authors note that psychotropic drugs, such as SSRI's, used by SMI patients 
have cardiovascular effects. Unfortunately, concomitant medications are not included in their 
database. Consider adding a bit more detail on how these drugs might promote MI or 
interfere with antiplatelet drugs, since cardiologists need to be aware of this, even though it is 
not directly related to the results of this study. 
 
Response: We have conducted a search on the association between psychotropic medications 
and MI and, while there is a clear association between the two, the evidence regarding 
pathophysiological mechanisms by which psychotropic medications could promote MI is 
sparse. We have now expanded the second paragraph of the ‘Discussion’ section to inform 
readers about the currently hypothesized mechanisms. The relevant addition reads as follows:  
 
“Antipsychotics and antidepressants such as SSRI’s (selective serotonin reuptake inhibitors) 
have been shown to increase the risk of metabolic syndrome due to their interaction with 
target 5-HT neuroreceptors that modulate weight control and glucose metabolism, which 
increases the risk of myocardial infarction. Furthermore, the use of antipsychotics (typical 
and atypical) has been associated with an increased risk of cerebrovascular events, 
especially in elderly patients, although the underlying mechanism remains unknown, while 
SSRI’s are thought to increase the uptake of serotonin into platelets leading to increased 
bleeding tendency.”  
 
 
Comment 6. In the SWEDEHEART Registry, the odds ratio for 30-day mortality in 
schizophrenia was 2.58 (1.88-3.54), much higher than the 10% increased risk that the authors 
report. Is it possible that the SWEDEHEART data is more relevant because follow-up 
includes hospital discharge to 30 days? 
 
Response: We thank the reviewer for highlighting this important observation. We believe 
that there are several reasons for the differences in risk or odds of mortality between our 
study and those reported in the SWEDEHEART study.  First, the SWEDEHEART registry 
included a very small number of patients compared to our study (SWEDEHEART vs. present 
study: Bipolar n=442 vs. 41,362; Schizophrenia n=541 vs. 23, 582) and these patients’ 
demographics and presentation were different to those found in our cohort, which makes it 
difficult to compare both studies. For example, the SWEDEHEART study only included 
patients with a first presentation of MI and had a significantly higher proportion of STEMI 
presentation amongst Schizophrenia and Bipolar patients. Furthermore, patients with 
Schizophrenia and Bipolar disorder in their analyses were significantly older with a higher 
prevalence of risk factors such as heart failure and previous stroke compared to our study. 
The baseline differences between both studies is likely attributable to their sample size rather 
than geographical differences and may have inflated their risk of mortality amongst both 
Schizophrenia and Bipolar disorder patients. However, we do agree that the risk of mortality 
may become more pronounced with longer follow up and we had already stated this in our 
‘Limitations section’ (quoted below). 
“Second, the ischemic benefits of an invasive strategy over a conservative 
management of AMI have been primarily shown in studies reporting at least 30-day follow 
up. Therefore, it is possible that SMI patients experience worse clinical outcomes in the long 
term than those reported in the present study that only captures in-hospital outcomes.” 
 
 
Comment 7. Figure 1A is unnecessary and could be deleted. 
 
Response: We agree with the reviewer that illustrating the prevalence of all-cause SMI is 
less useful compared to individual SMI subtypes and we have now removed this figure. 
Figure 1 now includes the prevalence of SMI from 2004 to 2014 according to subtype 
(previously Figure 1B).  
 
 
Comment 8. The authors refer to their study population as "contemporary" at several points 
in the paper. Perhaps 2004-2014 is not contemporary any more, but this is a minor quibble. 
 
Response: At the time of analysis, the latest available dataset was for 2016 as there is always 
a two-year lag in NIS data being sold for research use. We had not included the latter two 
years for two reasons. First, they were not accessible for our use. Second, the transition to 
ICD-10 diagnosis codes started in 2015 and, in view of the significant differences in the 
coding system, especially for mental health disorders, we felt that this may introduce a 
potential selection bias when combined with ICD-9 diagnoses in our analysis.  
However, we are in complete agreement with the reviewer in that the word ‘contemporary’ 
may not be accurate and we have removed all references to it from our manuscript. 
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Abbreviations 
 
ACS Acute Coronary Syndrome 
AHRQ Agency for Healthcare Research and Quality 
AMI Acute Myocardial Infarction 
CA Coronary Angiography 
CABG Coronary Artery Bypass Grafting 
CAD Coronary Artery Disease 
CVA Cerebrovascular Accident 
DAPT Dual Anti-Platelet Therapy 
MACCE Major Adverse Cardiovascular and Cerebrovascular 
Event  
NST-EACS Non –ST-elevation acute coronary syndrome 
OR Odds Ratio 
PCI Percutaneous Coronary Intervention 
RR Relative Risk or Risk Ratio 
SMI Severe Mental Illness(es) 
STEMI ST-elevation Myocardial Infarction 
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Abstract 
Background: Severe mental illness (SMI) is associated with increased cardiovascular 
mortality. We sought to examine the prevalence, clinical outcomes and management strategy 
of patients with SMI presenting with acute myocardial infarction (AMI).  
Methods: All AMI hospitalizations from the National Inpatient Sample were included, 
stratified by mental health status in to 5 groups: no-SMI, Schizophrenia, ‘Other non-organic 
psychoses’ (ONOP), Bipolar Disorder and Major Depression. Regression analyses were 
performed to assess the association (adjusted odds ratios, p≤0.001 for all outcomes) between 
SMI subtypes and clinical outcomes. 
Results: Out of 6,968,777 AMI hospitalizations between 2004 and 2014, 439,544 (6.5%) had 
an SMI diagnosis. Although patients with Schizophrenia and ONOP experienced higher 
crude rates of in-hospital mortality and stroke compared to those without SMI, only 
Schizophrenia patients were at increased odds of mortality (1.10[1.04,1.16]), while ONOP 
were the only group at increased odds of stroke (1.53[1.42,1.65]) following multivariate 
adjustment. Patients with ONOP were the only group associated with increased odds of in-
hospital bleeding compared to those without SMI (1.11[1.04,1.17]). All SMI subtypes were 
less likely to receive coronary angiography and PCI, with the Schizophrenia group being at 
least odds of either procedure (0.46[0.45,0.48] and 0.57[0.55,0.59], respectively). 
Conclusion: Schizophrenia and ‘other non-organic psychoses’ are the only SMI subtypes 
associated with adverse clinical outcomes after AMI. However, all patients with SMI were 
less likely to receive invasive management for AMI, with women and schizophrenia 
diagnosis being the strongest predictors of conservative management. A multidisciplinary 
approach between psychiatrists and cardiologists could improve outcomes of this high-risk 
population. 
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Condensed Abstract (<75 Words) 
Patients with severe mental illness (SMI) are a high-risk group for cardiovascular 
disease. The present study examined the prevalence and outcomes of SMI patients in a 
national AMI cohort. SMI has doubled in prevalence amongst AMI patients, mainly due to a 
rise in Major Depression and Bipolar Disorder. Only Schizophrenia and ‘Other non-organic 
psychoses’ groups were associated with worse outcomes, but all SMI subtypes were less 
likely to receive invasive management for their AMI.  
 
Introduction 
 Cardiovascular disease (CVD) is a major cause of morbidity and mortality in patients 
with severe mental illness (SMI), including Schizophrenia, Bipolar Disorder Major 
Depression and Psychosis and Delusional disorders.
1-4
 It is estimated that more than 10.4 
million adults (4.2% of all adults) suffer from SMI in the United States, with a similar 
worldwide prevalence of up to 6.8%. 5
, 
6 
Patients with SMI are reported to have a two- to three-fold increased risk of mortality 
from cardiovascular disorders compared to the general population, a risk that has increased 
over the past two decades.7 Acute myocardial infarction (AMI) is the commonest 
manifestation of CVD but there is limited literature on the prevalence, treatment strategies 
and clinical outcomes of patients with SMI who are often excluded from clinical trials due to 
concerns about their adherence to cardiovascular medications and follow-up.8 A nationwide 
analysis in patients with Schizophrenia and Bipolar Disorder presenting with ST-Elevation 
Myocardial Infarction (STEMI) demonstrated an increased mortality in patients with 
Schizophrenia and reduced odds of revascularization in both subgroups.9 Conversely, an 
analysis of elderly patients (>65 years) presenting with AMI showed that patients with mental 
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health disorders (Schizophrenia, affective disorders and substance abuse disorder) were not at 
increased risk of 30-day mortality, although they were also less likely to undergo coronary 
revascularization.10 
While previous studies have looked at the clinical outcomes of SMI in the context of 
AMI, they have demonstrated conflicting results and were subject to limitations such as 
analysis of selected cohorts (single ACS subtype, e.g. STEMI)9 or a single geographical 
region (e.g. State of Florida)11, inclusion of selected outcomes (e.g. only mortality)12, 
exclusion of patients with previous myocardial infarction12, or the analysis of small sample 
that may not be representative of the population of interest13. Furthermore, patients with SMI 
are a heterogenous population with differences in their underlying pathophysiology and 
pharmacotherapy according to their diagnosis subtype that may lead to divergent effects on 
their clinical outcomes in the context of AMI. The majority of studies have either 
investigated the overall effect of all-cause SMI 11
, 
14
, 
15 or analyzed individual mental health 
subtypes without a comparison of the relative risks of clinical outcomes according to SMI 
subtype.10 Finally, while some studies have looked at gender differences in reperfusion 
therapy 11
, 
12
, 
16, there have been no reports on differences in clinical outcomes of SMI 
patients after AMI according to gender.  
 The current study utilized a national cohort drawn from the National Inpatient Sample 
over an eleven-year period (2004-2014) to define the prevalence of patients with SMI 
presenting with AMI and examine their clinical characteristics, in-hospital outcomes and 
processes of care, stratified by subtype of SMI and further stratified by gender.  
 
Methods  
Data Source 
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The National Inpatient Sample (NIS), is the largest publicly available all-payer 
database of hospitalized patients in the United States and is sponsored by the Agency for 
Healthcare Research and Quality as a part of the Healthcare Cost and Utilization Project.17 
Further information about the design of NIS and its previous validation is available in the 
supplementary materials (Appendix A) .  
 
Study Design and Population 
A retrospective observational analysis of all AMI hospitalizations between 2004 and 
2014 from the NIS database was performed. Diagnoses and procedure variables were 
extracted using the relevant International Classification of Diseases, 9th Revision, Clinical 
Modification (ICD-9 CM) codes. The cohort was stratified into 5 groups; ‘No SMI’, 
Schizophrenia, Bipolar Disorder, ‘Other non-organic psychoses’ (ONOP) and ‘Major 
Depression’. Further information on the methods used to identify patient characteristics and 
procedural data and exclude missing cases is available in the supplementary material 
(Appendix B and Table S1) 
 
Outcomes 
The primary outcome measures were to define the prevalence of SMI in AMI and 
examine the clinical characteristics, comorbidity burden and in-hospital rates of major acute 
cardiovascular and cerebrovascular events (MACCE) (composite of mortality, acute 
stroke/transient ischemic attack (TIA) and cardiac complications) and all-cause bleeding. 
Cardiac complications included any pericardiocentesis, cardiac tamponade, hemopericardium 
and coronary dissection during hospitalization, while. bleeding was defined as any post-
procedural hemorrhage or hematoma, or bleeding requiring transfusion.  
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The secondary outcome was the evaluation of the receipt of coronary angiography 
(CA) and revascularization (percutaneous coronary intervention (PCI) and coronary artery 
bypass grafting (CABG)). 
 
Statistical Analysis 
For detailed statistical analysis methods and a list of the covariates adjusted for please 
refer to the supplementary material (Appendix C)  
Results 
A total of 6,738,757 patients were included in the final analysis (Figure S1). Patients 
with a diagnosis of SMI comprised 6.5% (n=439,544) of the study cohort. The patient 
characteristics of the study population are presented in the supplements (Table S2) according 
to the presence or absence of SMI, and SMI subtype; Schizophrenia (0.4%, n=23,582), 
Bipolar Disorder (0.3%, n=41,362), ONOP (0.6%, n=22,359) and Major Depression  (5.3%, 
n=352,241), the latter being the most common subtype. The prevalence of SMI amongst the 
ACS population doubled over the study period (from 4.5% in 2004 to 9.5% in 2014), 
primarily due to an increase in Major Depression and Bipolar Disorder diagnoses (Figure 1), 
while the prevalence of ONOP and Schizophrenia disorders has not changed. 
Several key differences in patient demographics are seen across the study groups. 
(Table S1, Appendix D)  
 
Utilization of invasive management 
 There was a notable increase in the rates of both coronary angiography and PCI in all 
the groups over the study period (Figure S2). However, in comparison to patients without 
SMI, the rates of coronary angiography and PCI were persistently lower in all SMI subtypes 
except those with Bipolar Disorder, whom overall were more likely to be offered coronary 
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angiography (67.1% vs. 64.4%, p<0.001) (Figure 2, Table S4). In multivariate analysis, all 
SMI subtypes were associated with reduced odds of coronary angiography and PCI, with 
Schizophrenia patients being the least likely to undergo either of the procedures (Figure 6, 
Table S6). 
 The rates of coronary angiography and PCI were also lower amongst women across 
all study groups, including patients without an SMI diagnosis (Figure 3), a finding that 
persisted in multivariate analysis (Table S7). However, the odds of receipt of coronary 
angiography between genders were not significant in the Schizophrenia and Major 
Depression groups.   
 
In-hospital MACCE, Mortality and Stroke 
Patients with ONOP and Schizophrenia experienced the highest rates of in-hospital 
MACCE (Figure 4), primarily driven by higher rates of mortality (6.4% and 7.5%) and stroke 
(4.0% and 2.2%) compared to other SMI subtypes and patients without SMI (p<0.001 for 
both). The lowest rates of MACCE, mortality and stroke were observed in patients with 
Bipolar Disorder (Table 1).  
In multivariate analysis, patients with ONOP and Major Depression were associated 
with significantly reduced odds of MACCE (0.86 [0.82, 0.90] and 0.86 [0.85, 0.88], 
respectively) (Figure 6, Table S6). However, both groups demonstrated a polar effect on 
Stroke, where patients with ONOP were at 53% increased odds of stroke and those with 
Major Depression associated with 16% reduced odds of stroke. There was no difference in 
either outcome (MACCE and stroke) in patients with Schizophrenia and Bipolar Disorder.  
Schizophrenia was the only subtype associated with increased odds of mortality (1.10 [1.04, 
1.16]), while all other SMI subtypes were associated with a significantly reduced odds of 
mortality. 
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In subgroup gender analysis, the rates of in-hospital MACCE, mortality and Stroke 
were consistently higher in women compared to men, except the rates of stroke in ONOP that 
were higher in men. (Figure 5, Table S4) In multivariable analysis, the odds of MACCE were 
increased in women without SMI and those with Bipolar Disorder and Major Depression, 
primarily driven by increased odds of acute stroke in these groups. (Table S7) In contrast to 
the other groups, women with ONOP were associated with reduced odds of MACCE and 
stroke compared to men (Table S7). Furthermore, women without SMI and those with ONOP 
and Major Depression were at reduced odds of mortality compared to men, while there was 
no difference in mortality between genders in the Schizophrenia and Bipolar Disorder groups.   
A temporal analysis of outcomes demonstrates an overall decline in the rates of 
MACCE, mortality and acute stroke/TIA in all the study groups except the ONOP and 
Bipolar disorder groups whose rates of MACCE and acute stroke/TIA have either increased 
or remained the same (Table S5). However, the pattern of differences in rates of MACCE, 
morality and stroke between groups remained the same throughout the study period. 
 
In-hospital Bleeding 
 In comparison to patients without SMI, only the ONOP group experienced higher 
rates of bleeding, while all other SMI subtypes experienced lower rates of bleeding (Figure 
4). Subgroup gender analysis demonstrated higher rates of bleeding amongst women in 
patients without SMI and those with Schizophrenia, and lower rates of bleeding amongst 
women in patients with Bipolar Disorder and ONOP. (Figure 5) There was no difference in 
crude rates of bleeding between both genders in patients with Major Depression. 
In multivariate analysis, only patients with ONOP were associated with an increased 
odds of bleeding (1.11 [1.04, 1.17], p=0.001) while all other SMI subtypes were at a 
significantly reduced odds of bleeding (Schizophrenia: 0.70 [0.65, 0.75]; Bipolar Disorder: 
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0.85 [0.81, 0.90]; Major Depression: 0.97 [0.95,0.98], p<0.001 for all outcomes) (Figure 6, 
Table S6). 
A multivariate analysis according to gender revealed increased odds of bleeding in 
women without SMI as well as those with Schizophrenia and Major Depression 
(Supplementary Material - Table S7). In contrast, no difference in bleeding was found 
between genders in patients with ONOP and women with Bipolar disorder were at reduced 
odds of bleeding.  
The rate of all-cause bleeding increased in all groups over the study period but 
remained higher in SMI groups compared to patients without SMI, with the exception of 
ONOP group whose rates of bleeding were higher than patients without SMI. (Table S5) 
 
Sensitivity Analysis 
 A sensitivity analysis according to AMI type (STEMI vs. NSTEMI) was performed to 
exclude examine differences in outcomes between both AMI presentations. Overall, the 
findings in the STEMI and NSTEMI groups were generally similar to those found in the total 
cohort. (Table S6) However, certain differences were observed within AMI subgroups. In the 
NSTEMI subgroup, patients with Bipolar Disorder were associated with reduced odds of 
MACCE compared to those without SMI while there was no difference in MACCE and all-
cause bleeding between patients without SMI and those with ONOP. In the STEMI subgroup, 
there was no difference in mortality and all-cause bleeding between patients with Bipolar 
Disorder group and those without SMI as was the case in all-cause bleeding between patients 
with Major Depression and those without SMI.  
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Discussion 
Our findings in the present study, drawn from a national cohort of acute coronary 
syndrome hospitalizations in the United States, show a significant rise in the prevalence of 
SMI patients presenting with AMI over the study period. We observe that patients with SMI 
represent a multi-morbid cohort that is higher in cardiovascular risk with a more significant 
burden of comorbidities than those without SMI. Our results demonstrate significant 
disparities in the clinical outcomes and utilization of invasive strategies amongst patients 
with severe mental illnesses, including Bipolar Disorder, ONOP, Schizophrenia and Major 
Depression. Furthermore, we report lower rates of invasive management (coronary 
angiography and PCI) in patients with SMI, who experience higher crude rates of adverse 
outcomes, including MACCE, mortality, bleeding and stroke, compared to those without a 
SMI diagnosis. However, after adjustment for confounders, patients with Schizophrenia were 
associated with increased odds of in-hospital mortality amongst all SMI subtypes, whilst 
patients with ONOP were the only SMI group at increased odds of stroke and bleeding 
complications following AMI. Finally, our analysis highlights a gender gap in clinical 
outcomes and invasive management strategy, with women being less likely to be offered 
early invasive strategies (coronary angiography and PCI) despite their higher risk of 
mortality.  
Patients with SMI are a heterogenous group with a multitude of pathological and 
socioeconomic risk factors for cardiovascular disease, depending on the subtype of SMI, and 
been shown to have a higher burden of risk factors such as diabetes, smoking, obesity and 
chronic kidney disease. 18-23 Furthermore, their use of psychotropic medications such as 
antipsychotics and selective serotonin reuptake inhibitors (SSRIs) places them at a higher risk 
of adverse outcomes including stroke, cardiovascular mortality and bleeding.
24-27
 
Antipsychotics and antidepressants such as SSRI’s (selective serotonin reuptake inhibitors) 
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have been shown to increase the risk of metabolic syndrome due to their interaction with 
target 5-HT neuroreceptors that modulate weight control and glucose metabolism, which 
increases the risk of myocardial infarction.28-30  Furthermore, the use of antipsychotics 
(typical and atypical) has been associated with an increased risk of cerebrovascular events, 
especially in elderly patients, although the underlying mechanism remains unknown, 31
, 
32, 
while SSRI’s are thought to increase the uptake of serotonin into platelets leading to 
increased bleeding tendency.33  In this national analysis of all hospitalizations with AMI in 
the US, we show that only more complex SMI subtypes such Schizophrenia were at increased 
odds of in-hospital mortality. A previous national analysis of the SWEDEHEART registry 
also demonstrated higher mortality in patients with Schizophrenia both at 30-day (OR 2.58 
[1.88-3.54)) and one-year (OR: 2.97 [2.39-3.69]) follow up in patients admitted following 
AMI.12 However, in contrast to our findings, patients with Bipolar Disorder (n=442) were 
also shown to be at greater odds of mortality in their analysis albeit only significant at 1-year 
follow-up (OR 1.62 [1.20-2.20]). In contrast, an analysis of approximately 800 veterans with 
SMI showed lower crude rates of 30 day mortality (4.6% vs. 6.2%) and higher 1-year 
mortality (15.3% vs. 13.2%) in SMI patients compared to those without any mental illness.14 
While their findings did not reach statistical significance, the marked difference in results 
between studies highlights the limitations of analyzing small and combined cohorts of all 
SMI. More importantly, not all the SMI subtypes are associated with increased mortality 
hazard in our analysis, with certain SMI subtypes such as Bipolar Disorder and Major 
Depression being at lower odds of in-hospital mortality compared to those without SMI.   
To the best of our knowledge, no previous study has examined stroke and bleeding 
outcomes in SMI patients after AMI. Our findings show that only patients with ONOP were 
at increased odds of bleeding and stroke, while all other SMI subtypes (Bipolar Disorder, 
Schizophrenia and Major Depression) were at lower odds of both outcomes compared to no 
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SMI. A plausible explanation could be the greater use of psychotropic medications in patients 
with psychosis that is known to be associated with increased odds of adverse cardiovascular 
events, especially in elderly patients, although the underlying mechanism remains unknown. 
31
, 
32 Similarly, the use of selective serotonin reuptake inhibitors (SSRI’s) is known to 
promote the uptake of serotonin into platelets leading to an increase in bleeding tendency.33  
The lower frequency of stroke and bleeding in SMI subtypes other than ONOP could be 
explained by the low rates of invasive coronary management in these patients. Although we 
have adjusted for the differences in patient demographics and receipt of revascularization, 
there could be residual unmeasured confoundment that accounts for these findings. 
Our gender subgroup analysis highlights persistent differences in invasive management 
strategies and in clinical outcomes of both SMI and non-SMI patients. We found women in 
all study group to be associated with lower or insignificant odds of mortality compared to 
men, but also at increased odds of acute stoke/TIA, except in those with ONOP where the 
was no difference between genders. Women with Schizophrenia were also associated with 
the highest odds of bleeding complications compared to men. However, women of all 
subgroups were much less likely to undergo invasive management compared to men, 
especially women with Bipolar Disorder who were 15% and 34% less likely to receive 
coronary angiography and PCI, respectively. Despite the lack of evidence on gender 
outcomes in this population, a possible explanation for our findings is the higher prevalence 
of comorbidities predisposing to bleeding and stroke amongst women as seen in our patients’ 
demographics. However, the disparities in clinical outcomes according to gender highlights 
the need for prospective studies to explore the underlying pathophysiological mechanisms 
that may lead to these differences in patients with SMI.     
The present study is the first to examine the prevalence of SMI in the AMI population 
and shows a rise in the prevalence of SMI over an eleven-year horizon, primarily due 
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increasing rates of Major Depression and Bipolar disorder diagnoses. Although these findings 
are in keeping with previous reports of trends in the general population,34-36 it is possible 
that that these diagnoses have been coded more frequently in later years due to physicians’ 
awareness of their implications in the context of AMI hospitalizations.  
The lower rates of invasive management (coronary angiography and PCI) in patients 
with SMI may be due to several reasons. It is possible that patients suffering from SMI lack 
the ability to engage in the discussions required for informed consent for such procedures. 
Furthermore, their lack of recognition and diagnostic overshadowing in emergency services 
leads to delayed presentations of their acute myocardial infarction. Patients undergoing PCI 
are committed to a minimum duration of dual antiplatelet therapy as well as other secondary 
prevention pharmacotherapy, regular follow up and access to cardiac rehabilitation to 
optimize their response to pharmacotherapy and success of their coronary intervention 
37, 38
 
However, patients with SMI are previously reported to have poor compliance with diet 
advice, cardiac medications and rehabilitation, which often leads to physicians’ reluctance to 
offer them coronary intervention.4
, 
10
, 
15 Consequently, patients with SMI who do not 
undergo in-hospital invasive management are at an even greater risk of adverse clinical 
outcomes after AMI, including higher rates of mortality and future re-infarction.
37-39
 
However, only few studies have compared these management strategies across different SMI 
subtypes, while the majority have examined the association of all-cause SMI with odds of 
reperfusion therapy. 10
, 
11
, 
15 For example, Campi et al. reported reduced odds of 
reperfusion therapy (PCI, thrombolysis or CABG; OR 0.70 [0.60,0.80]) in patients with 
charted mental illnesses (composite of Schizophrenia, Bipolar, and Depressive disorders; 
n=1036) presenting with AMI across the state of Florida.11 While these findings were 
significant, they did not inform of SMI subgroups with the least odds of receiving invasive 
coronary management. We show that patients with SMI of all subtypes were consistently less 
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likely to be offered an invasive management strategy (coronary angiography and PCI) over 
the study decade 
40-42
 The lowest odds of invasive management (coronary angiography and 
PCI) were in patients with Schizophrenia, although they were at the greatest risk of mortality 
in our study. An individualized patient-based approach is required to assess these complex 
patients to improve utilization of guideline-recommended therapy in this high-risk group.  
 
Limitations 
 The are several limitations to the present study. First, the NIS is an administrative 
dataset that is susceptible to coding. Although the identification of ACS and SMI diagnoses 
as well as other comorbidities was based on the use of administrative codes, ICD-9 codes 
have been previously validated for the purposes of cardiovascular research.
43, 44
 Second, the 
ischemic benefits of an invasive strategy over a conservative management of AMI have been 
primarily shown in studies reporting at least 30-day follow up.
39, 45, 46
 Therefore, it is possible 
that SMI patients experience worse clinical outcomes in the long term than those reported in 
the present study that only captures in-hospital outcomes. Third, since the NIS dataset does 
not capture pharmacotherapy, we were unable to determine differences in the use of 
antithrombotic therapy between the study groups. Finally, we have not been able to assess the 
severity of the mental health illness or the overlap of mental health diagnoses, which remain 
as potential residual confounders. Nevertheless, we believe that our findings provide insight 
into the ‘real world’ in-hospital clinical outcomes of a large and unselected ACS cohort with 
severe mental illness. 
 
Conclusion 
 Our analysis a national cohort of acute coronary syndrome hospitalizations shows a 
disparity of clinical outcomes amongst patients with severe mental illness and identifies 
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patients with Schizophrenia and ‘other non-organic psychoses’ as those with the poorest 
outcomes, namely higher in-hospital mortality and in-hospital stroke, respectively. 
Furthermore, we conclude that patients with SMI are less likely to be offered an invasive 
management strategy, with women of all SMI subtypes and patients with Schizophrenia 
being the most disadvantaged groups.  
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Table 1. In-hospital clinical outcomes and Quality Indicators according to subtype of SMI 
 No SMI Schizophrenia ONOP Bipolar disorder 
Major 
depression 
Total 
p-
value 
MACCE, % 8.0 9.6 10.6 5.6 6.7 7.9 <0.001 
Cardiac 
complications, % 
0.7 0.4 0.6 0.8 0.6 0.7 <0.001 
Acute stroke/TIA, % 1.7 2.2 4.0 1.5 1.8 1.7 <0.001 
Mortality, % 6.0 7.5 6.4 3.4 4.6 5.9 <0.001 
All-cause bleeding, 
% 
5.3 3.8 6.3 4.4 5.1 5.2 <0.001 
Use of assist device 
or IABP, % 
5.0 4.0 4.9 3.9 3.3 4.9 <0.001 
Shock, % 5.0 6.1 5.4 4.0 3.6 4.9 <0.001 
Receipt of coronary 
angiography, % 
64.4 46.8 42.9 67.1 59.5 64.0 <0.001 
Receipt of PCI, % 42.9 27.2 23.0 42.4 36.9 42.5 <0.001 
Receipt of CABG, % 8.5 5.4 10.9 7.0 6.9 8.4 <0.001 
Discharge against 
medical advice (%) 
0.8 2.5 1.5 2.7 0.8 0.8 <0.001 
CABG: coronary artery bypass grafting; MACCE: major adverse cardiovascular and cerebrovascular events (composite of mortality, acute 
stroke/transient and cardiac complications); ONOP: Other Non-Organic Psychoses; PCI: percutaneous coronary angiography; TIA: transient 
ischemic attack 
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Figure Legends 
Figure 1. Prevalence of SMI from 2004 to 2014 according to subtype  
Legend: ONOP: Other non-organic psychoses 
 
Figure 2. Receipt of coronary angiography (CA) and percutaneous coronary 
intervention (PCI) 
Legend: ONOP: Other non-organic psychoses; SMI: Severe mental illness 
 
Figure 3. Receipt of coronary angiography (CA) and PCI according to SMI subtype and 
gender 
Legend: ONOP: Other non-organic psychoses; SMI: Severe mental illness 
 
Figure 4. In-hospital adverse events according to SMI subtype 
Legend: ONOP: Other non-organic psychoses; SMI: Severe mental illness 
 
Figure 5. In-hospital adverse events according to gender 
Legend: ONOP: Other non-organic psychoses; SMI: Severe mental illness 
 
Figure 6. Odds ratio (95% CI) of adverse outcomes according to SMI subtype 
Legend: *Reference group is No-SMI; § non-significant (p≥0.05); † p<0.001; CI: 
confidence interval; ONOP: Other non-organic psychoses 
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